Inscripta isn't just another biotech startup; it's a company that has completely reinvented itself. After shedding its legacy identity as a genomic editing firm, it has re-emerged as 'Manus'—a high-stakes player betting $459.5 million on replacing petrochemicals with biology.

"With just 21 employees and nearly half a billion in funding, Manus is executing one of the most capital-intensive, labor-efficient strategies in biotech."

The leadership team reflects this scientific heavy-hitting approach. With Richard Fox as Chief Scientist and Benjamin Borgo leading Mammalian Biology, the focus is clearly on deep R&D rather than flashy marketing. The $1.6M in revenue against $459.5M in funding indicates they are in a heavy investment phase, likely subsidizing early pilot programs to prove the efficacy of their bioalternatives to major manufacturers.

• The 'Manus' Rebrand: A deliberate move away from the crowded genomics space into the high-value chemical market.
• Enterprise-First Traffic: Low global rank but high direct traffic suggests a B2B model reliant on closed-door partnerships, not inbound marketing.
• Capital Efficiency vs. Scale: A $21.8M valuation per employee ratio implies they are hoarding capital for expensive lab infrastructure and long-term R&D cycles.